Guideline Updates for the Management of *Clostridioides difficile* Infection and Severe SARS-CoV-2 Infection

1. Discuss the evidence supporting recent IDSA/SHEA and ACG guideline updates for the management of *Clostridioides difficile* infection (CDI).
2. Apply recent guideline recommendations to critically ill patients with CDI.
3. Assess severity of illness in patients with SARS-CoV-2 infection to guide antiviral and immunomodulatory pharmacotherapy decisions.
4. Discuss guideline updates and primary evidence for using antiviral and immunomodulatory therapies in patients with severe SARS-CoV-2 infection.

Pulmonary Disorders II: Stop Dates, Revoked Recommendations, Steroids, and More

1. Design an antimicrobial treatment plan appropriate for cystic fibrosis (CF) pulmonary exacerbations (PEx).
2. Identify appropriate adjunct therapies for cystic fibrosis (CF) pulmonary exacerbations (PEx) based on recently published literature.
3. Evaluate treatment options for pulmonary hypertension (PH) based on current literature and guideline recommendations.
4. Recognize changes in the management and treatment of acute and chronic asthma supported by current guidelines and literature.